Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events

On May 26, 2022, Y-mAbs Therapeutics, Inc., (the "Company") issued a press release announcing data from the naxitamab-based chemoimmunotherapy trial in patients with chemoresistant high-risk neuroblastoma ("HR-NB"), that Dr. Shakeel Modak, MD from Memorial Sloan Kettering ("MSK") will present at the American Society of Clinical Oncology ("ASCO") Annual Meeting to be held June 3-7, 2022. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 8.01 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.      Description

  99.1             Press Release, dated May 26, 2022, issued by Y-mAbs
                 Therapeutics, Inc.

104              Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses